WithdrawnPhase 3NCT00089518
Optimal Treatment for Kidney Disease in HIV Infected Adults
Studying REN-related autosomal dominant tubulointerstitial kidney disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Lynda Anne Szczech, MD, MSCEDivision of Nephrology, Department of Medicine, Duke University Medical Center
- Intervention
- Valsartan(drug)
- Eligibility
- 18 years · All sexes
Study locations (10)
- Indiana University Hospital, Indianapolis, Indiana, United States
- Methodist Hospital of Indiana, Indianapolis, Indiana, United States
- Wishard Hospital, Indianapolis, Indiana, United States
- Washington University (St. Louis), St Louis, Missouri, United States
- NYU/Bellevue, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- MetroHealth Medical Center, Cleveland, Ohio, United States
- Rhode Island Hospital, Providence, Rhode Island, United States
- Stanley Street Treatment and Resource, Providence, Rhode Island, United States
- The Miriam Hospital, Providence, Rhode Island, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00089518 on ClinicalTrials.govOther trials for REN-related autosomal dominant tubulointerstitial kidney disease
Additional recruiting or active studies for the same condition.
See all trials for REN-related autosomal dominant tubulointerstitial kidney disease →